ak112
mAbexperimentalMulti-specific
Clinical trial activity
120 trials · 58 clinical orgs · 0 marketing orgs
Phase 1
25
Phase 2
111
Phase 3
15
Phase 4
1
Earliest trial started Aug 15, 2019 (NCT04047290)
Timeline
Indications
Studied for
- Antibodies, Monoclonal · Phase 2
- Biliary Tract Neoplasms · Phase 3
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma, Adenoid Cystic · Phase 2
- Carcinoma, Hepatocellular · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Small Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Drug Evaluation · Phase 1/Phase 2
- Drug Therapy · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- General Surgery · Phase 2
- Genital Neoplasms, Female · Phase 2
- Glioblastoma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Immune Checkpoint Inhibitors · Phase 2
- Immunotherapy · Phase 2
- Lung Neoplasms · Phase 2
- Melanoma · Phase 1
- Mesothelioma · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Radiation · Phase 2
- Rectal Neoplasms · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Stomach Neoplasms · Phase 2
- Thymus Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068451 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226544 | Phase 2 | Jun 8, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07234877 | Phase 2 | Apr 30, 2026 | European Organisation for Research and Treatment of Cancer, Maastricht University, Summit Therapeutics |
| NCT07158489 | Phase 2 | Mar 1, 2026 | Swiss Cancer Institute |
| NCT07264075 | Phase 3 | Jan 31, 2026 | Akeso Pharmaceuticals, Inc., Groupe Oncologie Radiotherapie Tete et Cou, Summit Therapeutics |
| NCT07057791 | Phase 2 | Dec 31, 2025 | PrECOG, LLC., Summit Therapeutics, University of Maryland |
| NCT07070466 | Phase 2 | Dec 12, 2025 | Harvard University, Summit Therapeutics |
| NCT07244965 | Phase 2 | Dec 1, 2025 | Zhejiang University |
| NCT07244978 | Phase 2 | Dec 1, 2025 | Zhejiang University |
| NCT07241819 | Phase 2 | Nov 30, 2025 | Peking University |
| NCT07094685 | Phase 2 | Nov 18, 2025 | Summit Therapeutics, University of Michigan |
| NCT07228832 | Phase 3 | Nov 15, 2025 | Summit Therapeutics |
| NCT07204548 | Phase 2 | Oct 31, 2025 | Sun Yat-Sen University |
| NCT07208773 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2025 | Akeso Pharmaceuticals, Inc., Suzhou Medilink Therapeutics Ltd. |
| NCT07245446 | Phase 2 | Oct 29, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT07229417 | Phase 2 | Oct 22, 2025 | University of Texas at Houston |
| NCT06846346 | Phase 2 | Sep 30, 2025 | Institut Paoli-Calmettes, Summit Therapeutics, UNICANCER |
| NCT07103447 | Phase 2 | Sep 10, 2025 | Sichuan University |
| NCT07158840 | Phase 2 | Sep 5, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT07162714 | Phase 2 | Sep 1, 2025 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT07114315 | Phase 2 | Aug 31, 2025 | Akeso Pharmaceuticals, Inc. |
Showing 20 of 120 trials
Page 1 / 6
Organizations
Research & Development (58)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 47 | 37 | 3 | 2019 |
| Summit Therapeutics | For profit | 21 | 5 | 2 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 12 | 9 | 3 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 8 | 3 | 1 | 2021 |
| Fudan University | Academic/Hospital | 7 | 6 | 2 | 2024 |
| University of Texas at Houston | Academic/Hospital | 6 | 6 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 5 | 3 | 2 | 2021 |
| Sichuan University | Academic/Hospital | 5 | 5 | 1 | 2024 |
| Tianjin Medical University | Academic/Hospital | 5 | 5 | 1 | 2024 |
| Harbin Medical University | Academic/Hospital | 3 | 2 | 1 | 2023 |
| Nanjing University | Academic/Hospital | 3 | 3 | 2 | 2024 |
| Peking University | Academic/Hospital | 3 | 3 | 2 | 2024 |
| Central South University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Chongqing Medical University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Fujian Medical University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 2 | 1 | 1 | 2023 |
| Shandong University | Academic/Hospital | 2 | 1 | 1 | 2021 |
| UNICANCER | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2025 |
58 organizations
Page 1 / 3